Long-term outcomes of Sleeping Beauty-generated CD19-specific CAR T-cell therapy for relapsed-refractory B-cell lymphomas.
作者信息
Srour S A, Singh H, McCarty J, de Groot E, Huls H, Rondon G, Qazilbash M, Ciurea S, Bardelli G, Buck J, Alousi A, Nieto Y, Rezvani K, Marin D, Popat U, Hosing C, Shpall E J, Wierda W G, Kantarjian H, Champlin R E, Cooper L J, Kebriaei P
机构信息
Department of Stem Cell Transplantation and Cellular Therapy and.
Department of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, TX.
出版信息
Blood. 2020 Mar 12;135(11):862-865. doi: 10.1182/blood.2019002920.
Abstract
摘要
相似文献
1
Long-term outcomes of Sleeping Beauty-generated CD19-specific CAR T-cell therapy for relapsed-refractory B-cell lymphomas.用于复发难治性B细胞淋巴瘤的睡美人转座子系统生成的CD19特异性嵌合抗原受体T细胞疗法的长期疗效
Blood. 2020 Mar 12;135(11):862-865. doi: 10.1182/blood.2019002920.
2
Chimeric Antigen Receptor T-Cell Therapies for Aggressive B-Cell Lymphomas: Current and Future State of the Art.用于侵袭性B细胞淋巴瘤的嵌合抗原受体T细胞疗法：当前与未来的技术水平
Am Soc Clin Oncol Educ Book. 2019 Jan;39:446-453. doi: 10.1200/EDBK_238693. Epub 2019 May 17.
3
Updates on CAR T-cell therapy in B-cell malignancies.嵌合抗原受体 T 细胞疗法治疗 B 细胞恶性肿瘤的最新进展。
Immunol Rev. 2019 Jul;290(1):39-59. doi: 10.1111/imr.12774.
4
Efficacy and toxicity for CD22/CD19 chimeric antigen receptor T-cell therapy in patients with relapsed/refractory aggressive B-cell lymphoma involving the gastrointestinal tract.CD22/CD19 嵌合抗原受体 T 细胞疗法治疗累及胃肠道的复发/难治性侵袭性 B 细胞淋巴瘤患者的疗效和毒性。
Cytotherapy. 2020 Mar;22(3):166-171. doi: 10.1016/j.jcyt.2020.01.008. Epub 2020 Feb 13.
5
CD19 chimeric antigen receptor-T cells in B-cell leukemia and lymphoma: current status and perspectives.嵌合抗原受体 T 细胞治疗 B 细胞白血病和淋巴瘤：现状与展望。
Leukemia. 2019 Dec;33(12):2767-2778. doi: 10.1038/s41375-019-0615-5. Epub 2019 Nov 5.
6
Anti-CD19 chimeric antigen receptors T cells for the treatment of relapsed or refractory E2A-PBX1 positive acute lymphoblastic leukemia: report of three cases.抗 CD19 嵌合抗原受体 T 细胞治疗复发或难治性 E2A-PBX1 阳性急性淋巴细胞白血病：三例报告。
Leuk Lymphoma. 2019 Jun;60(6):1454-1461. doi: 10.1080/10428194.2018.1533127. Epub 2019 Feb 4.
7
Challenges of driving CD30-directed CAR-T cells to the clinic.将 CD30 导向 CAR-T 细胞推向临床应用所面临的挑战。
BMC Cancer. 2019 Mar 6;19(1):203. doi: 10.1186/s12885-019-5415-9.
8
In Vivo Fate and Activity of Second- versus Third-Generation CD19-Specific CAR-T Cells in B Cell Non-Hodgkin's Lymphomas.体内第二代与第三代 CD19 特异性 CAR-T 细胞在 B 细胞非霍奇金淋巴瘤中的命运和活性。
Mol Ther. 2018 Dec 5;26(12):2727-2737. doi: 10.1016/j.ymthe.2018.09.009. Epub 2018 Sep 13.
9
Tumor-Specific Reactive Oxygen Species Accelerators Improve Chimeric Antigen Receptor T Cell Therapy in B Cell Malignancies.肿瘤特异性活性氧物种加速器改善嵌合抗原受体 T 细胞疗法在 B 细胞恶性肿瘤中的应用。
Int J Mol Sci. 2019 May 18;20(10):2469. doi: 10.3390/ijms20102469.
10
Managing the toxicities of CAR T-cell therapy.管理嵌合抗原受体 T 细胞疗法的毒性。
Hematol Oncol. 2019 Jun;37 Suppl 1:48-52. doi: 10.1002/hon.2595.
引用本文的文献
1
Safety and Efficacy of CD19-Targeted Chimeric Antigen Receptor (CAR) T-cells Generated Using DNA Transposon Systems: A Meta-Analysis.使用DNA转座子系统生成的CD19靶向嵌合抗原受体（CAR）T细胞的安全性和有效性：一项荟萃分析。
Cureus. 2025 Apr 8;17(4):e81930. doi: 10.7759/cureus.81930. eCollection 2025 Apr.
2
Cost-effective strategies for CAR-T cell therapy manufacturing.嵌合抗原受体T细胞（CAR-T）疗法生产的经济高效策略。
Mol Ther Oncol. 2025 Apr 3;33(2):200980. doi: 10.1016/j.omton.2025.200980. eCollection 2025 Jun 18.
3
The development and application of chimeric antigen receptor natural killer (CAR-NK) cells for cancer therapy: current state, challenges and emerging therapeutic advances.嵌合抗原受体自然杀伤（CAR-NK）细胞在癌症治疗中的开发与应用：现状、挑战及新兴治疗进展
Exp Hematol Oncol. 2024 Dec 4;13(1):118. doi: 10.1186/s40164-024-00583-7.
4
Updates in Immunotherapy for Pancreatic Cancer.胰腺癌免疫治疗的进展
J Clin Med. 2024 Oct 26;13(21):6419. doi: 10.3390/jcm13216419.
5
TCR-T cell therapy: current development approaches, preclinical evaluation, and perspectives on regulatory challenges.T 细胞受体嵌合型 T 细胞疗法：当前的开发方法、临床前评估，以及监管挑战的观点。
J Transl Med. 2024 Oct 4;22(1):897. doi: 10.1186/s12967-024-05703-9.
6
Empowering virus-free CAR immune cell therapies.赋能无病毒嵌合抗原受体免疫细胞疗法。
Mol Ther. 2024 Jun 5;32(6):1609-1611. doi: 10.1016/j.ymthe.2024.05.023. Epub 2024 May 25.
7
A Naturally Active Spy Transposon Discovered from the Insect Genome of Colletes gigas as a Promising Novel Gene Transfer Tool.从 Colletes gigas 昆虫基因组中发现的一种自然活跃的转座子，可作为一种有前途的新型基因转移工具。
Adv Sci (Weinh). 2024 Aug;11(29):e2400969. doi: 10.1002/advs.202400969. Epub 2024 May 22.
8
Evolution of the clinical-stage hyperactive TcBuster transposase as a platform for robust non-viral production of adoptive cellular therapies.临床阶段过表达 TcBuster 转座酶的进化作为一种稳健的非病毒生产过继细胞疗法的平台。
Mol Ther. 2024 Jun 5;32(6):1817-1834. doi: 10.1016/j.ymthe.2024.04.024. Epub 2024 Apr 16.
9
Combined therapy of CAR-IL-15/IL-15Rα-T cells and GLIPR1 knockdown in cancer cells enhanced anti-tumor effect against gastric cancer.嵌合抗原受体修饰的 IL-15/IL-15Rα-T 细胞联合 GLIPR1 敲低的肿瘤细胞对胃癌的抗肿瘤作用增强。
J Transl Med. 2024 Feb 18;22(1):171. doi: 10.1186/s12967-024-04982-6.
10
Microphysiological systems for solid tumor immunotherapy: opportunities and challenges.用于实体瘤免疫治疗的微生理系统：机遇与挑战
Microsyst Nanoeng. 2023 Dec 15;9:154. doi: 10.1038/s41378-023-00616-x. eCollection 2023.
本文引用的文献
1
CD19 CAR T cells following autologous transplantation in poor-risk relapsed and refractory B-cell non-Hodgkin lymphoma.自体移植后 CD19 CAR T 细胞治疗高危复发/难治性 B 细胞非霍奇金淋巴瘤。
Blood. 2019 Aug 15;134(7):626-635. doi: 10.1182/blood.2018883421. Epub 2019 Jul 1.
2
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial.阿基仑赛注射液治疗难治性大 B 细胞淋巴瘤的长期安全性和疗效（ZUMA-1）：一项单臂、多中心、1-2 期临床试验。
Lancet Oncol. 2019 Jan;20(1):31-42. doi: 10.1016/S1470-2045(18)30864-7. Epub 2018 Dec 2.
3
Novel therapies for relapsed/refractory aggressive lymphomas.复发/难治侵袭性淋巴瘤的新型治疗方法。
Hematology Am Soc Hematol Educ Program. 2018 Nov 30;2018(1):75-82. doi: 10.1182/asheducation-2018.1.75.
4
Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma.Tisagenlecleucel 治疗成人复发或难治性弥漫性大 B 细胞淋巴瘤。
N Engl J Med. 2019 Jan 3;380(1):45-56. doi: 10.1056/NEJMoa1804980. Epub 2018 Dec 1.
5
Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study.难治性弥漫性大B细胞淋巴瘤的预后：国际SCHOLAR-1研究结果
Blood. 2017 Oct 19;130(16):1800-1808. doi: 10.1182/blood-2017-03-769620. Epub 2017 Aug 3.
6
A randomized phase II study of standard-dose versus high-dose rituximab with BEAM in autologous stem cell transplantation for relapsed aggressive B-cell non-hodgkin lymphomas: long term results.一项关于标准剂量与高剂量利妥昔单抗联合BEAM方案用于复发侵袭性B细胞非霍奇金淋巴瘤自体干细胞移植的随机II期研究：长期结果
Br J Haematol. 2017 Aug;178(4):561-570. doi: 10.1111/bjh.14731. Epub 2017 May 9.
7
Diffuse large B-cell lymphoma with primary treatment failure: Ultra-high risk features and benchmarking for experimental therapies.初治失败的弥漫性大B细胞淋巴瘤：超高危特征及实验性疗法的基准研究
Am J Hematol. 2017 Feb;92(2):161-170. doi: 10.1002/ajh.24615.
8
Phase I trials using Sleeping Beauty to generate CD19-specific CAR T cells.使用睡美人转座子系统生成CD19特异性嵌合抗原受体T细胞的I期试验。
J Clin Invest. 2016 Sep 1;126(9):3363-76. doi: 10.1172/JCI86721. Epub 2016 Aug 2.
9
Phase 1 studies of central memory-derived CD19 CAR T-cell therapy following autologous HSCT in patients with B-cell NHL.B细胞非霍奇金淋巴瘤患者自体造血干细胞移植后中枢记忆来源的CD19嵌合抗原受体T细胞疗法的1期研究。
Blood. 2016 Jun 16;127(24):2980-90. doi: 10.1182/blood-2015-12-686725. Epub 2016 Apr 26.
10
Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era.利妥昔单抗时代复发的大 B 细胞淋巴瘤的自体移植挽救治疗方案。
J Clin Oncol. 2010 Sep 20;28(27):4184-90. doi: 10.1200/JCO.2010.28.1618. Epub 2010 Jul 26.
Zotero 插件